FibroGen

Our CEO, Thane Wettig, will participate in a Fireside Chat at the @ H.C. Wainwright 2nd Annual BioConnect Investor Conference May 20 at 1:30 PM ET. Listen to the webcast here: bit.ly/4dM0yDS

FibroGen management to participate at upcoming investor conferences. Read the details here: bit.ly/3UPyGqQ

Today #FibroGen announced first quarter 2024 financial results. We are committed to accelerating the development of novel therapies at the frontiers of cancer biology. Read more about our announcement:

FibroGen announced today that they will report first quarter 2024 results on May 6. Read more details in the press release. bit.ly/4dag5wO

Today we come together on World Pancreatic Cancer Day to unite the globe in bringing attention to pancreatic cancer and highlighting the need for greater awareness, funding, and research. @FibroGen is committed to research that addresses the unmet needs. #PANCAware

#PanCANawareness On World Pancreatic Cancer Day (Nov. 16), our partner, @PanCAN, is hosting a free, virtual event where researchers, clinicians and survivors will discuss the latest in early detection for #pancreaticcancer. 💜Don't miss it! RSVP today at pancan.org/wpcd2023

It's Pancreatic Cancer Awareness Month! FibroGen is joining @PanCAN in educating about early detection. Know the signs and symptoms, know your risk and know your family history- it can save your life. 💜 Learn more at pancan.org/awareness

Today #FibroGen announced our third quarter financial results. We are committed to the pursuit of groundbreaking research and science to drive forward a pipeline that may transform patient outcomes. Read more about our announcement: bit.ly/45XfBWd

November is Pancreatic Cancer Awareness Month. Approximately 65,000 Americans are expected to be diagnosed with pancreatic cancer in 2023. #FibroGen is committed to research that addresses the unmet needs of the pancreatic cancer community. #PANCAware #purpleforapurpose

FibroGen announced today that they will report third quarter 2023 results. Read more details in the press release. Read the details here: bit.ly/3QsOYnp

FibroGen CEO, Enrique Conterno will participate in a Fireside Chat at the upcoming @Jefferies Global Healthcare Conference on June 8. #JefferiesHealthcare Read the details here

Today FibroGen announced first quarter financial results and provided an update on recent developments and pipeline. Read more about the announcement:

FibroGen will report first quarter 2023 financial results on May 8. Read more details in the press release.

@FibroGenInc, today announced the completion of patient enrollment for ZEPHYRUS-2, a Phase 3 clinical study in patients with idiopathic pulmonary fibrosis. Read the press release here. bit.ly/3U4UNaQ

Excited to be here in Dallas at @mdaorg’s 2023 MDA Clinical & Scientific Conference, where we are representing FibroGen. #MDAconference #DMD Learn more about our research into #duchennemusculardystrophy #DMD and the role of connective tissue growth factor (#CTGF)

#Duchenne muscular dystrophy (#DMD) is a genetic disorder characterized by progressive muscle fibrosis and resulting weakness. FibroGen is committed to research to disrupt the fibrosis process and supporting patients who currently have limited treatment options.

Our CMO, Dr. Mark Eisner, will participate in panel discussion at Cowen's 43rd Annual Health Care Conference on Wednesday, March 8 at 10:30 AM Eastern Time. Listen to the webcast: bit.ly/41PSX0Z

Our CEO, Enrique Conterno, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16 at 3:40 PM Eastern Time. Listen to the webcast: bit.ly/3I46idc

January is Pancreatic Cancer Clinical Trials Awareness Month. FibroGen is committed to developing therapeutics targeting pancreatic cancer.

From all of us at FibroGen, we extend our warmest holiday wishes to you and your loved ones this holiday season.